Status:
COMPLETED
Metabolic Signatures and Biomarkers in Schizophrenia
Lead Sponsor:
Duke University
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
We plan to use a metabolomics lipid platform to map biochemical signatures in unmedicated schizophrenic patients prior to and 4 weeks post treatment with the antipsychotic drug aripiprazole and compar...
Detailed Description
Schizophrenia (SCH) is a devastating mental disease that affects the human population worldwide with an incidence of about 1%. Most individuals with this illness benefit from long-term pharmacotherapy...
Eligibility Criteria
Inclusion
- Age 18-60 years
- Diagnosis of schizophrenia
- Actively psychotic
- No more than a single dose of antipsychotic in the preceding 2 weeks
Exclusion
- Mental retardation, epilepsy or history of head trauma
- Substance use disorder that explains the majority of the psychopathology
- Pregnant or lactating females
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT00466310
Start Date
February 1 2007
End Date
January 1 2011
Last Update
July 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
John Umstead Hospital
Butner, North Carolina, United States, 27509